Next Article in Journal
Synthesis, physico-chemical properties and bioloclical activitv of 1-(4-fluorophenvl)-4-[3-(2-,3- and 4-alkyloxyphenylcarbamoyloxy)-2-hydroxypropyl] piperaziniumchlorides
Previous Article in Journal
lnvestiaations for the Preparation of new Pyrazolo[4,3-d]isothiazole Derivatives
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 73
Issue 1
10.3797/scipharm.aut-05-05
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Vitro Evaluation of Sustained Released Matrix Tablet Formulations of Clarithromvcin

by
Lütfi Genç
* and
A. Muhittin Kıran
Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 26470, Eskişehir, Turkey
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2005, 73(1), 59-74; https://doi.org/10.3797/scipharm.aut-05-05
Submission received: 20 February 2004 / Accepted: 1 December 2005 / Published: 30 March 2005
Versions Notes

Abstract

Sustained release matrix tablets of clarithromycin were prepared using different polymers as Hydroxypropyl methylcellulose (H PMC), Carbopol 934 and Eudragit RL/PO by direct compression technique. For the quality control of these formulations, weight deviation, hardness, friability, diameter-height ratio, content uniformity of the active substance and in vitro dissolution technique were performed. HPLC was used for the assay of clarithromycin and the assay method was validated. Dissolution profiles of the tablets were plotted and evaluated kinetically. The effects on drug release of polymer type and concentrations were investigated by 23 factorial design. The tablets containing HPMC, Carbopol 934 and Eudragit RLIPO were found suitably to sustain drug release
Keywords: Sustained release; Matrix tablet; Clarithromycin; 23 factorial design; Validation Sustained release; Matrix tablet; Clarithromycin; 23 factorial design; Validation

Share and Cite

MDPI and ACS Style

Genç, L.; Kıran, A.M. In Vitro Evaluation of Sustained Released Matrix Tablet Formulations of Clarithromvcin. Sci. Pharm. 2005, 73, 59-74. https://doi.org/10.3797/scipharm.aut-05-05

AMA Style

Genç L, Kıran AM. In Vitro Evaluation of Sustained Released Matrix Tablet Formulations of Clarithromvcin. Scientia Pharmaceutica. 2005; 73(1):59-74. https://doi.org/10.3797/scipharm.aut-05-05

Chicago/Turabian Style

Genç, Lütfi, and A. Muhittin Kıran. 2005. "In Vitro Evaluation of Sustained Released Matrix Tablet Formulations of Clarithromvcin" Scientia Pharmaceutica 73, no. 1: 59-74. https://doi.org/10.3797/scipharm.aut-05-05

APA Style

Genç, L., & Kıran, A. M. (2005). In Vitro Evaluation of Sustained Released Matrix Tablet Formulations of Clarithromvcin. Scientia Pharmaceutica, 73(1), 59-74. https://doi.org/10.3797/scipharm.aut-05-05

Article Metrics

Back to TopTop